ODAC support for myeloma metric makes broader case for endpoint innovation

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

The clinical development toolkit for multiple myeloma is expanding with an FDA advisory committee’s unanimous support for a new accelerated approval endpoint. The change could shave years off development timelines and incentivize investment in early treatment lines. The move highlights the growing need for endpoint innovation in the face of improving standard-of-care treatments across cancer indications...